

C Janneke Van Der Woude

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9036593/c-janneke-van-der-woude-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

134
papers

5,043
citations

37
h-index

67
g-index

142
ext. papers

6,269
ext. citations

5.8
avg, IF

5.42
L-index

#	Paper	IF	Citations
134	Value-based care pathway for inflammatory bowel disease: a protocol for the multicentre longitudinal non-randomised parallel cluster IBD Value study with baseline period.. <i>BMJ Open</i> , 2022 , 12, e050539	3	0
133	Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn's Disease: A Pooled Analysis of 6 Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	4
132	Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 3548-3554	4	2
131	Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	2
130	Ustekinumab for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2021 , 15, 1920-1930	1.5	7
129	Impact of the Coronavirus Disease Pandemic on Health-Related Quality of Life of Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	1
128	Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 234-248	6.1	5
127	Alterations in Fecal Microbiomes and Serum Metabolomes of Fatigued Patients With Quiescent Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 519-527.e5	6.9	11
126	Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, e25	4.5	
125	Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life. <i>Gut</i> , 2021 , 70, 1266-1274	19.2	7
124	Decreasing Trends in Intestinal Resection and Re-Resection in Crohn's Disease: A Nationwide Cohort Study. <i>Annals of Surgery</i> , 2021 , 273, 557-563	7.8	7
123	Systematic review with meta-analysis: effect of inflammatory bowel disease therapy on lipid levels. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 999-1012	6.1	2
122	Thromboembolic and atherosclerotic cardiovascular events in inflammatory bowel disease: epidemiology, pathogenesis and clinical management. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211032126	4.7	2
121	Patient sex does not affect endoscopic outcomes of biologics in inflammatory bowel disease but is associated with adverse events. <i>International Journal of Colorectal Disease</i> , 2020 , 35, 1489-1500	3	3
120	Limited added value of laboratory monitoring in thiopurine maintenance monotherapy in inflammatory bowel disease patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 1353-1364	6.1	3
119	Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 880-888	6.1	26
118	Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 123-134	6.1	38

117	Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry - Vedolizumab. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 1189-1199	6.1	13
116	Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 129-138	6.1	43
115	Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 637-646.e11	6.9	46
114	Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1704-1718	6.9	8
113	Diagnosis and Outcome of Oesophageal Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 624-629.	5	1
112	Ozanimod in Crohn's disease: a promising new player. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 791-792	18.8	1
111	Autologous Platelet-Rich Stroma in Complex Perianal Fistulas. <i>Diseases of the Colon and Rectum</i> , 2020 , 63, 860-861	3.1	1
110	Intestinal resection rates in Crohn's disease decline across two different epidemiological areas: a consistent observation not merely due to introduction of anti-TNF. <i>Gut</i> , 2020 , 69, 1	19.2	2
109	High Immunogenicity to Influenza Vaccination in Crohn's Disease Patients Treated with Ustekinumab. <i>Vaccines</i> , 2020 , 8,	5.3	24
108	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 179-187.e6	6.9	24
107	Long-term Evaluation of Allogeneic Bone Marrow-derived Mesenchymal Stromal Cell Therapy for Crohn's Disease Perianal Fistulas. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 64-70	1.5	43
106	Longitudinal Trajectory of Fatigue With Initiation of Biologic Therapy in Inflammatory Bowel Diseases: A Prospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 309-315	1.5	13
105	Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2019 , 157, 997-1006.e6	13.3	51
104	Fecal Matrix Metalloproteinase-9 Measurement for Optimizing Detection of Disease Activity in Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2019 , 53, 395-397	3	1
103	A Direct Effect of Sex Hormones on Epithelial Barrier Function in Inflammatory Bowel Disease Models. <i>Cells</i> , 2019 , 8,	7.9	24
102	Off-label prescriptions of drugs used for the treatment of Crohn's disease or ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 1293-1300	6.1	5
101	Pregnancy, psychiatry and IBD: multidisciplinary care is crucial. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 265-266	24.2	1
100	Epithelial endoplasmic reticulum stress orchestrates a protective IgA response. <i>Science</i> , 2019 , 363, 993-998	33.5	37

99	Comment on "Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease". <i>Inflammatory Bowel Diseases</i> , 2019 , 25, e59	4.5	1
98	Effect of Cognitive Behavioral Therapy on Clinical Disease Course in Adolescents and Young Adults With Inflammatory Bowel Disease and Subclinical Anxiety and/or Depression: Results of a Randomized Trial. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 1945-1956	4.5	8
97	Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 407-415	6.1	12
96	Isolated ileal blind loop inflammation after intestinal resection with ileocolonic anastomosis in Crohn's disease: an often neglected endoscopic finding with an unfavorable outcome. <i>European Journal of Gastroenterology and Hepatology</i> , 2019 , 31, 1370-1375	2.2	2
95	Health Care Transition Outcomes in Inflammatory Bowel Disease: A Multinational Delphi Study. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, 1163-1172	1.5	15
94	Modulatory Effects of Pregnancy on Inflammatory Bowel Disease. <i>Clinical and Translational Gastroenterology</i> , 2019 , 10, e00009	4.2	9
93	Health-related quality of life in the first 5 years of the children born to mothers with IBD does not differ from children born to healthy mothers. <i>Journal of Psychosomatic Research</i> , 2019 , 127, 109840	4.1	0
92	Cholecystectomy Risk in Crohn's Disease Patients After Ileal Resection: a Long-term Nationwide Cohort Study. <i>Journal of Gastrointestinal Surgery</i> , 2019 , 23, 1840-1847	3.3	2
91	Fatigue in IBD: epidemiology, pathophysiology and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 247-259	24.2	68
90	Methotrexate and Thioguanine Rescue Therapy for Conventional Thiopurine Failing Ulcerative Colitis Patients: A Multi-center Database Study on Tolerability and Effectiveness. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 1558-1565	4.5	3
89	Genomic and Expression Analyses Identify a Disease-Modifying Variant for Fibrostenotic Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 582-588	1.5	8
88	Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease-an International, Cross-disciplinary Consensus. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 408-418	1.5	66
87	Low dose Naltrexone for induction of remission in inflammatory bowel disease patients. <i>Journal of Translational Medicine</i> , 2018 , 16, 55	8.5	30
86	Correlating Fecal Calprotectin With Hemoglobin Levels Within 1 Sample. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 663	4.5	
85	TNF- α exerts potent anti-rotavirus effects via the activation of classical NF- κ B pathway. <i>Virus Research</i> , 2018 , 253, 28-37	6.4	19
84	IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. <i>Nature Communications</i> , 2018 , 9, 2427	17.4	95
83	Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 939-947	1.5	23
82	Pregnant women with inflammatory bowel disease: the effects of biologicals on pregnancy, outcome of infants, and the developing immune system. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018 , 12, 811-818	4.2	16

81	Defective ATG16L1-mediated removal of IRE1 α drives Crohn's disease-like ileitis. <i>Journal of Experimental Medicine</i> , 2017 , 214, 401-422	16.6	109
80	Prevalence and Phenotype of Concurrent Psoriasis and Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 1783-1789	4.5	39
79	Endoscopy for Inflammatory Bowel Disease During Pregnancy: Only When There Is a Strong Indication. <i>Gastroenterology</i> , 2017 , 153, 330-331	13.3	1
78	Use of Thiopurines During Conception and Pregnancy Is Not Associated With Adverse Pregnancy Outcomes or Health of Infants at One Year in a Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1232-1241.e1	6.9	29
77	Analysis of SHIP1 expression and activity in Crohn's disease patients. <i>PLoS ONE</i> , 2017 , 12, e0182308	3.7	13
76	Fatigue in patients with inflammatory bowel disease is associated with distinct differences in immune parameters. <i>Clinical and Experimental Gastroenterology</i> , 2017 , 10, 83-90	3.1	21
75	Sex Is Associated with Adalimumab Side Effects and Drug Survival in Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 75-81	4.5	10
74	Cohort profile: design and first results of the Dutch IBD Biobank: a prospective, nationwide biobank of patients with inflammatory bowel disease. <i>BMJ Open</i> , 2017 , 7, e016695	3	20
73	An unexpected cause of terminal ileitis. <i>Gastrointestinal Endoscopy</i> , 2017 , 85, 453	5.2	
72	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 135-149 ⁵	1.5	387
71	6-methylmercaptopurine-induced leukocytopenia during thiopurine therapy in inflammatory bowel disease patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 1183-1190	4	19
70	IBD: Exposure to anti-TNF agents in utero: controlling health risks. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016 , 13, 387-8	24.2	5
69	Safety of Tioguanine During Pregnancy in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016 , 10, 159-65	1.5	7
68	Preconception Care Reduces Relapse of Inflammatory Bowel Disease During Pregnancy. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1285-1292.e1	6.9	65
67	Similar Depletion of Protective Faecalibacterium prausnitzii in Psoriasis and Inflammatory Bowel Disease, but not in Hidradenitis Suppurativa. <i>Journal of Crohn's and Colitis</i> , 2016 , 10, 1067-75	1.5	98
66	The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. <i>Gastroenterology</i> , 2016 , 150, 734-757.e1	13.3	261
65	Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up. <i>PLoS ONE</i> , 2016 , 11, e0142481	3.7	72
64	Increased PTP1B expression and phosphatase activity in colorectal cancer results in a more invasive phenotype and worse patient outcome. <i>Oncotarget</i> , 2016 , 7, 21922-38	3.3	33

63	Convergent Transcription of Interferon-stimulated Genes by TNF- α and IFN- γ Augments Antiviral Activity against HCV and HEV. <i>Scientific Reports</i> , 2016 , 6, 25482	4.9	35
62	Characteristics of Patients With Hidradenitis Suppurativa and Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 482-3	6.9	2
61	Does lower gastrointestinal endoscopy during pregnancy pose a risk for mother and child? - a systematic review. <i>BMC Gastroenterology</i> , 2015 , 15, 15	3	24
60	Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells Promote Healing of Refractory Perianal Fistulas in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2015 , 149, 918-27.e6	13.3	186
59	Self-reported disability in patients with inflammatory bowel disease largely determined by disease activity and illness perceptions. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 369-77	4.5	37
58	Comparison of Costs and Quality of Life in Ulcerative Colitis Patients with an Ileal Pouch-Anal Anastomosis, Ileostomy and Anti-TNF Therapy. <i>Journal of Crohn's and Colitis</i> , 2015 , 9, 1016-23	1.5	21
57	Benefit of Earlier Anti-TNF Treatment on IBD Disease Complications?. <i>Journal of Crohn's and Colitis</i> , 2015 , 9, 997-1003	1.5	21
56	Incidence of Interval Colorectal Cancer Among Inflammatory Bowel Disease Patients Undergoing Regular Colonoscopic Surveillance. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1656-61	6.9	52
55	The Role of Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Alpha Agents in Children and Adolescents with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 2214-21	4.5	16
54	Predicting Endoscopic Disease Activity in Crohn's Disease: A New and Validated Noninvasive Disease Activity Index (The Utrecht Activity Index). <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 2453-9	4.5	10
53	Low molecular weight protein tyrosine phosphatase (LMWPTP) upregulation mediates malignant potential in colorectal cancer. <i>Oncotarget</i> , 2015 , 6, 8300-12	3.3	27
52	Linkage between genotype and immunological phenotype in Crohn's disease. <i>Annals of Translational Medicine</i> , 2015 , 3, 237	3.2	1
51	Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). <i>Gut</i> , 2014 , 63, 292-9	19.2	162
50	Management of gastrointestinal and liver diseases during pregnancy. <i>Gut</i> , 2014 , 63, 1014-23	19.2	25
49	Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. <i>Gut</i> , 2014 , 63, 451-7	19.2	94
48	Genomic ATG16L1 risk allele-restricted Paneth cell ER stress in quiescent Crohn's disease. <i>Gut</i> , 2014 , 63, 1081-91	19.2	91
47	N-ECCO survey results of nursing practice in caring for patients with Crohn's disease or ulcerative colitis in Europe. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, 1300-7	1.5	18
46	Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation. <i>Gut</i> , 2014 , 63, 1424-30	19.2	18

45	Suppression of p21Rac signaling and increased innate immunity mediate remission in Crohn's disease. <i>Science Translational Medicine</i> , 2014 , 6, 233ra53	17.5	22
44	Effect of aging on healthcare costs of inflammatory bowel disease: a glimpse into the future. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 637-45	4.5	10
43	Drug therapies for ulcerative proctitis: systematic review and meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 2157-78	4.5	13
42	Disappointing durable remission rates in complex Crohn's disease fistula. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 2022-8	4.5	84
41	Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF therapy: results from the COIN study. <i>Gut</i> , 2014 , 63, 72-9	19.2	348
40	Risk factors of work disability in patients with inflammatory bowel disease--a Dutch nationwide web-based survey: work disability in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, 590-7	1.5	42
39	Increased suppressor of cytokine signaling-3 expression predicts mucosal relapse in ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 132-40	4.5	11
38	Extracorporeal photopheresis (ECP) in patients with steroid-dependent Crohn's disease: an open-label, multicenter, prospective trial. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 293-300	4.5	37
37	Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 318-21	6.9	103
36	Do pregnancy-related changes in the microbiome stimulate innate immunity?. <i>Trends in Molecular Medicine</i> , 2013 , 19, 454-9	11.5	29
35	Reply to Drs. Silva and Santana's letter. <i>Journal of Crohn's and Colitis</i> , 2013 , 7, e152	1.5	
34	The cell biology of the intestinal epithelium and its relation to inflammatory bowel disease. <i>International Journal of Biochemistry and Cell Biology</i> , 2013 , 45, 798-806	5.6	17
33	Peripheral neutrophil functions and cell signalling in Crohn's disease. <i>PLoS ONE</i> , 2013 , 8, e84521	3.7	31
32	Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 152-60	4.5	55
31	Absence of ABCG2-mediated mucosal detoxification in patients with active inflammatory bowel disease is due to impeded protein folding. <i>Biochemical Journal</i> , 2012 , 441, 87-93	3.8	27
30	CD64 distinguishes macrophages from dendritic cells in the gut and reveals the Th1-inducing role of mesenteric lymph node macrophages during colitis. <i>European Journal of Immunology</i> , 2012 , 42, 3150-66	6.1	352
29	SOCS3 in immune regulation of inflammatory bowel disease and inflammatory bowel disease-related cancer. <i>Cytokine and Growth Factor Reviews</i> , 2012 , 23, 127-38	17.9	36
28	Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: results from an international survey and discussion programme. <i>Journal of Crohn's and Colitis</i> , 2012 , 6, 116-31	1.5	13

27	Disease severity does not affect the interval between IBD diagnosis and the development of CRC: results from two large, Dutch case series. <i>Journal of Crohn's and Colitis</i> , 2012 , 6, 435-40	1.5	9
26	Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus. <i>Journal of Crohn's and Colitis</i> , 2012 , 6, 248-58	1.5	32
25	Single-balloon enteroscopy, magnetic resonance enterography, and abdominal US useful for evaluation of small-bowel disease in children with (suspected) Crohn's disease. <i>Gastrointestinal Endoscopy</i> , 2012 , 75, 87-94	5.2	46
24	STAT1, STAT6 and adenosine 3',5'-cyclic monophosphate (cAMP) signaling drive SOCS3 expression in inactive ulcerative colitis. <i>Molecular Medicine</i> , 2012 , 18, 1412-9	6.2	16
23	New insights into the role of STAT3 in IBD. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 1177-83	4.5	31
22	Integrated models of care in managing inflammatory bowel disease: a discussion. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 1582-7	4.5	42
21	Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 2026-33	4.5	100
20	Bone cells from patients with quiescent Crohn's disease show a reduced growth potential and an impeded maturation. <i>Journal of Cellular Biochemistry</i> , 2012 , 113, 2424-31	4.7	4
19	Small bowel Crohn's disease: MR enteroclysis and capsule endoscopy compared to balloon-assisted enteroscopy. <i>Abdominal Imaging</i> , 2012 , 37, 397-403		33
18	Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 335-41	6.1	82
17	IL-6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer. <i>Carcinogenesis</i> , 2012 , 33, 1889-96	4.6	90
16	Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2012 , 18, 6967-73	5.6	18
15	Solution focused therapy: a promising new tool in the management of fatigue in Crohn's disease patients psychological interventions for the management of fatigue in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2011 , 5, 585-91	1.5	44
14	Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease. <i>PLoS ONE</i> , 2011 , 6, e23745	3.7	89
13	Impeded protein folding and function in active inflammatory bowel disease. <i>Biochemical Society Transactions</i> , 2011 , 39, 1107-11	5.1	14
12	Biomarker-based prediction of inflammatory bowel disease-related colorectal cancer: a case-control study. <i>Cellular Oncology (Dordrecht)</i> , 2011 , 34, 107-17	7.2	23
11	Anti-inflammatory actions of phosphatidylinositol. <i>European Journal of Immunology</i> , 2011 , 41, 1047-57	6.1	22
10	Misclassification of dysplasia in patients with inflammatory bowel disease: consequences for progression rates to advanced neoplasia. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 1108-16	4.5	43

9	Role of defective autophagia and the intestinal flora in Crohn disease. <i>Self/nonsel</i> , 2010 , 1, 323-327		3
8	European evidenced-based consensus on reproduction in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2010 , 4, 493-510	1.5	118
7	A short course of corticosteroids prior to surveillance colonoscopy to decrease mucosal inflammation in inflammatory bowel disease patients: results from a randomized controlled trial. <i>Journal of Crohn's and Colitis</i> , 2010 , 4, 661-8	1.5	11
6	Inflammatory bowel disease-patients are insufficiently educated about the basic characteristics of their disease and the associated risk of colorectal cancer. <i>Digestive and Liver Disease</i> , 2010 , 42, 777-84	3.3	28
5	Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1708-16	4.5	34
4	Surgery is Indicated for Persistent Enterocutaneous Fistulizing Crohn's Disease. <i>Clinical Medicine Gastroenterology</i> , 2008 , 1, CGast.S452		
3	Biologics in Crohn's disease: searching indicators for outcome. <i>Expert Opinion on Biological Therapy</i> , 2007 , 7, 1233-43	5.4	4
2	Are we ready for top-down therapy for inflammatory bowel diseases: pro. <i>Expert Review of Gastroenterology and Hepatology</i> , 2007 , 1, 243-8	4.2	4
1	So where is all the Cancer?222-225		1